Updated: Controversial opioid Zohydro ER pulled from the market
As the Belgian pharma UCB recently inked a $1.9 billion deal to buy out Zogenix and its top drug for epilepsy, the company’s former controversial opioid has now been pulled from the market, according to a Federal Register filing by the FDA on Tuesday.
Hydrocodone-based Zohydro ER — which initially won FDA approval in 2013 despite not having abuse-deterrent properties and despite an 11-2 adcomm vote against approval — is now one of 29 new drug applications from multiple sponsors that have decided to pull their drugs from the market for various reasons, according to the filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.